Authors
Latest:
Dr. DeCamp on Platforms of Surgical Management in Lung CancerMalcolm McAvoy DeCamp, Jr, MD, chief of Thoracic Surgery in the Department of Surgery, Northwestern University Feinberg School of Medicine, discusses different platforms of surgical management in the treatment of patients with lung cancer.
Latest:
Dr. Mason on Next Steps Following 10-Year PROTECT Study Data in Prostate CancerMalcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses next steps following the 10-year PROTECT study data for patients with prostate cancer.
Latest:
Dr. Ross on the Unmet Needs in Uterine CarcinosarcomaMalcolm Ross, MD, University of Pittsburgh, discusses unmet needs for patients with uterine carcinosarcoma.
Latest:
Dr. Mason on the Significant Results from the PROTECT Study in Prostate CancerMalcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.
Latest:
Dr. Harigopal on Advances With Breast Cancer PathologyMalini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.
Latest:
Exciting Data in the Treatment of HER2-low from SABCS 2023Laura Spring, MD, and Manali Bhave, MD, highlight promising new systemic treatment options on the horizon for patients with metastatic breast cancer, including T-DM1 for HER2-low disease, the AKT inhibitor capivasertib, and novel endocrine therapies.
Latest:
Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab BiosimilarManfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.
Latest:
Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal CancerManish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.
Latest:
Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPCManish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Latest:
Dr. Patel on Key Updates from First-Line Trials in NSCLCManish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.
Latest:
Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal CancerManish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.
Latest:
Dr. Paul Discusses the Pulmonologist's Role in Managing Patients With Lung CancerManju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).
Latest:
Novel Agents Show Signs of Efficacy Against Brain MetastasesAlthough many new therapies have been introduced in a range of cancer types, brain metastases remain a serious neurological complication in patients with advanced malignancies.
Latest:
Dr. Jain on the Use of Diagnostic Tracers in Prostate CancerManoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.
Latest:
Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial CancerMansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.
Latest:
Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic CancerManuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.
Latest:
Dr. Hidalgo Medina on Promising Research in Pancreatic CancerManuel Hidalgo Medina, MD, PhD, discusses some of the exciting pancreatic cancer research presented at the 2020 ACCR Virtual Annual Meeting I.
Latest:
Dr. Schmidinger on RCC Therapy Toxicity ManagementManuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).
Latest:
Differentiating Molecular Risk Assessments of Prostate CancerMarc A. Bjurlin, DO, clinical assistant professor, Department of Urology, NYU Langone Medical Center, discusses differentiating molecular risk assessments for patients with prostate cancer.
Latest:
Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced MelanomaMarc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.
Latest:
Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease DevelopmentMarc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.
Latest:
Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRCMarc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).
Latest:
Adjuvant Therapy for Biliary Tract Cancers AdvanceBiliary tract cancers are rare but deadly diseases, subdivided into intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma.
